For medical device companies, FDA review time is more than a number on a performance chart, it can determine how quickly an innovation reaches patients. MDUFA V promised to make the regulatory process more efficient, predictable, and transparent. Now, an independent assessment by Booz Allen Hamilton provides a detailed look at what actually changed. The headline is encouraging: FDA met the relevant MDUFA V commitments assessed in the report. But the more interesting story is what happened underneath that headline—and what sponsors should learn from it.
The five key takeaways from the report are as follows:
1. FDA is making the review process more interactive, and more digital. One of the clearest themes is a move away from a purely sequential “submit and wait” model. FDA continued expanding interactive review and resources designed to facilitate communication between reviewers and applicants. The results are notable: the percentage of 510(k)s meeting substantive-interaction performance goals increased from 87% in FY2021 to 96% in FY2024, while PMA Originals and Panel-Track Supplements increased from 79% to 100%.
At the same time, eSTAR has become increasingly central to submission preparation, with mandatory use for 510(k)s and De Novo requests and meaningful improvements in first-cycle acceptance. Hence, the submission quality and sponsor-FDA interaction increasingly matter together.
2. Deficiency letters are becoming more structured and actionable. MDUFA V placed significant emphasis on making deficiency communications clearer. FDA strengthened the Four-Part Harmony framework, clarified expectations for statements of basis, and reinforced supervisory review. The assessment also describes how audit findings were translated into updated procedures and training, for example, replacing vague statements such as “does not function as intended” with device-specific explanations. For sponsors, that matters. A clearer deficiency should mean a clearer regulatory question, and potentially a more focused response.
3. The Q-Submission process is becoming more disciplined. The updated Q-Submission guidance draws a sharper line between issues that warrant a formal Pre-Submission and questions that can be addressed through informal communication. Booz Allen reviewed 86 Pre-Submissions and found that they were appropriately scoped and aligned with the new recommendations. The practical message is straightforward: not every question needs a Pre-Sub. Sponsors should reserve the formal mechanism for substantive issues where documented FDA feedback can materially influence development strategy.
4. FDA is building infrastructure for the next generation of devices. Digital health, AI/ML, patient science, and real-world evidence are no longer peripheral topics. They are becoming embedded in the regulatory infrastructure. FDA expanded digital-health expertise and training, including AI/ML, software, interoperability, PCCPs, and emerging technologies. The RWE program similarly expanded guidance, training, and transparency around the use of real-world data in regulatory decision-making. For innovators, this creates opportunities, but also raises the bar for evidence strategy.
5. “Commitment met” does not necessarily mean “problem solved.” This may be the most important takeaway. FDA met its commitments, but Total Time to Decision remains complicated. The assessment found that average FDA and industry days appeared generally lower during MDUFA V than MDUFA IV, yet FDA missed the FY2024 510(k) TTD goal and the FY2023 PMA TTD goal. Methodological changes and lingering pandemic effects contributed to the results, and the report notes limitations in the available data.
In other words, regulatory modernization is producing measurable improvements, but faster review is not simply an FDA problem, or an FDA metric. Sponsors’ submission quality, responsiveness, communication, and development strategy also influence the total journey.
The MDUFA V assessment paints a picture of an FDA that is steadily modernizing how medical devices are reviewed. The biggest changes are not limited to review clocks; they include better digital tools, more structured communication, clearer deficiencies, stronger expertise, and new approaches to AI, RWE, and patient-centered evidence. For medical device companies, these changes reward sponsors that engage FDA early and arrive with well-structured, strategically focused submissions. The assessment also reminds us that meeting a regulatory commitment is not the same as eliminating every source of delay or uncertainty. The next competitive advantage may therefore belong to companies that understand not only what FDA requires, but how to work effectively within the evolving MDUFA V regulatory ecosystem.
